JAZZ PHARMACEUTICALS PLC (JAZZ)       157.77  +1.11 (+0.71%)

3 Cannabis Stocks With Double-Digit Percentage Revenue Growth

Their shares may be down, but their sales are up.

The Ultimate Growth Stocks to Buy With $300 Right Now

These three companies should deliver inflation-busting long-term growth.

2 Promising New Growth Stocks to Watch in 2023

These stocks have plenty of room to run.

Jazz Pharma, Zymeworks post 84% overall survival for cancer candidate (NASDAQ:JAZZ)

Jazz Pharmaceuticals (JAZZ) and Zymeworks (ZYME) announced 84% overall survival for zanidatamab, an experimental therapy for gastroesophageal adenocarcinoma. Read the full story here.

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease...

2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher

There are still plenty of growth opportunities left for these businesses.

These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.

These stocks look cheap if you take a long-term view.

Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 41st Annual J.P. Morgan...

2 Cannabis Stocks to Buy for the Long Haul

Don't give up on this sector too quickly.

2 Growth Stocks to Buy Heading Into 2023

These biotechs are far from having achieved their full potential.

2 Top Biotech Stocks to Buy for the Long Haul

These mid-cap biotechs are solid long-term choices.

Better Buy: Moderna vs Axsome

Revenue prospects look promising for both of these biotech companies.

Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with...

After Jumping 100%, Is Axsome a Buy Before 2023?

Axsome's revenue story is just getting started.

JAZZ stock upgraded at Goldman Sachs on outlook for operating margins (NASDAQ:JAZZ)

Jazz Pharmaceuticals (JAZZ) traded higher pre-market Friday after Goldman Sachs upgraded the Ireland-based biopharma to Buy from Neutral. Read the full story here.

2 Unstoppable Growth Stocks to Buy in 2022 and Beyond

These biotech players beat the bear market this year.

3 Fierce Stocks That Are Screaming Buys in December

Here are three winners in the making.

JAZZ Makes Notable Cross Below Critical Moving Average

Avadel stock surges 13% as Jefferies upgrades on opportunity to dent Jazz's market share

Avadel Pharmaceuticals (AVDL) stock rose ~13% on Wednesday after Jefferies Financial upgraded the shares to Buy from Hold on opportunity of taking market share from Jazz...

Struggling Axsome Stock Could Bounce Back on Drug Trial Success

Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.

Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations,...

Want to Double Your Money? Buying These Stocks Could be a Genius Move

These stocks are undervalued considering their long-term growth potential.

Prediction: This Growth Stock Could Double in 2023

The next year should be a busy one for this drugmaker.

Three CBD Stocks to Dominate a Budding Industry

The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity.